

NOV 02 1978

WORLD HEALTH
ORGANIZATION



ORGANISATION MONDIALE
DE LA SANTÉ

1211 GENEVA 27 - SWITZERLAND
Telegr.: UNISANTE-Geneva

1211 GENÈVE 27 - SUISSE
Télégr.: UNISANTÉ-Genève

Tél. 34 60 61 Télex. 27821

In reply please refer to:

Prière de rappeler la référence: B3/449/0/6
Your Ref: ABS/tak

26 October 1978

Dear Albert,

... Thank you for sending me a copy of a letter you have written to Dr Stojković, and your handwritten note, of 10 October. I enclose a copy of the letter I have written to Dr Stojković in order to make progress with the establishment of this laboratory.

I quite agree that it would be much better for two specialists, such as yourself and Professor Archetti, to look at the slides and that it is important also for Professor Archetti to visit Belgrade once again to discuss the matter with the Senior Pathologist who was absent on our last visit in September.

I was interested to see that you would advise against a blanket statement for practical determinations of dose in Hep 2 titres which should be reduced four- to sixfold as suggested by Ellisberg. There is no doubt that in some titrations, primary monkey kidney can be as sensitive as Hep 2, but Hep 2 being a more standardized cell substrate gives more reproducible results.

I look forward to receiving your data on Hep 2 titrations and spinal neurovirulence results quite soon. I should also be interested in hearing the outcome of your discussions with John Furesz of 15-17 October.

Kindest regards,

Yours sincerely,

Dr F. T. Perkins
Chief, Biologicals

Dr A. B. Sabin
Medical University of South Carolina
171 Ashley Avenue
Charleston
South Carolina 29403
United States of America

... Encl. as stated.

P7/452/3 GEN

25 October 1978

Dear Dr Stojkovic,

I think I should let you know what transpired at the meeting of the WHO Consultative Group on Oral Poliomyelitis Vaccine concerning the approval of your laboratory in Belgrade.

The consultants were very pleased about the description of the laboratory and the method of production you are using but they were quite concerned about the report on the lack of lesions seen in the monkeys after the inoculation of the vaccine.

I was given permission to approve the laboratory only after we had resolved this problem. I think it is important for us to have a consultant such as Professor Archetti to go to Belgrade and to look at all the sections of ~~the~~ consecutive loss and to see whether the consultant agrees that the scoring method used by your histopathologist is similar to those used elsewhere.

It will be important also for us to have a look particularly at those batches of vaccine that have been tested by a number of control authorities such as that in London. I would be grateful if you would inform me whether you agree with this plan and to identify by number those batches of vaccine that you ~~have~~ have been tested in monkeys by other national control authorities. In this way, we will be able to make progress towards the establishment of Torlak Laboratory.

Yours sincerely,

Dr F.T. Perkins
Chief, Biologicals

Dr Lj. Stojkovic
Institute of Immunology and Virology
Torlak
Belgrade
Yugoslavia